venBio Partners

Latest statistics and disclosures from venBio Partners's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are Rayzebio, ALXO, PHVS, HRMY, SLRN, and represent 99.71% of venBio Partners's stock portfolio.
  • Added to shares of these 1 stock: PHVS (+$18M).
  • Reduced shares in these 1 stock: VTYX (-$26M).
  • Sold out of its position in VTYX.
  • venBio Partners was a net seller of stock by $-8.0M.
  • venBio Partners has $667M in assets under management (AUM), dropping by 89.19%.
  • Central Index Key (CIK): 0001776382

Tip: Access up to 7 years of quarterly data

Positions held by venBio Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for venBio Partners

venBio Partners holds 7 positions in its portfolio as reported in the December 2023 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Rayzebio 48.1 $321M 5.2M 62.17
 View chart
Alx Oncology Hldgs (ALXO) 21.6 $144M 9.7M 14.89
 View chart
Pharvaris N V (PHVS) 20.7 $138M +15% 4.9M 28.05
 View chart
Harmony Biosciences Hldgs In (HRMY) 5.0 $33M 1.0M 32.30
 View chart
Acelyrin (SLRN) 4.3 $29M 3.9M 7.46
 View chart
Elevation Oncology (ELEV) 0.2 $1.6M 2.9M 0.54
 View chart
Impel Neuropharma (IMPLQ) 0.1 $341k 2.8M 0.12
 View chart

Past Filings by venBio Partners

SEC 13F filings are viewable for venBio Partners going back to 2019

View all past filings